Symbols / KAPA $0.44 +2.09% Kairos Pharma, Ltd.

Healthcare • Biotechnology • United States • ASE
KAPA Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. John S. Yu M.D., Ph.D.
Exch · Country ASE · United States
Market Cap 9.42M
Enterprise Value 5.55M
Income -5.84M
Sales —
FCF (ttm) -1.81M
Book/sh 0.30
Cash/sh 0.17
Employees 1
Insider 10d —
IPO Sep 16, 2024
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -0.66
PEG —
P/S —
P/B 1.44
P/C —
EV/EBITDA -0.95
EV/Sales —
Quick Ratio 8.53
Current Ratio 10.31
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -0.30
EPS next Y -0.67
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-13
Earnings (prior) 2026-05-13
ROA -54.78%
ROE -93.84%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 21.41M
Shs Float 12.42M
Insider Own 37.20%
Instit Own 6.94%
Short Float 1.08%
Short Ratio 0.88
Short Interest 157.34K
52W High 2.11
vs 52W High -79.15%
52W Low 0.43
vs 52W Low 2.33%
Beta —
Impl. Vol. —
Rel Volume 0.29
Avg Volume 130.68K
Volume 38.19K
Target (mean) $8.00
Tgt Median $8.00
Tgt Low $4.00
Tgt High $12.00
# Analysts 2
Recom None
Prev Close $0.43
Price $0.44
Change 2.09%
About

Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops immunotherapy and cell therapies for the treatment of cancer. The company offers therapeutics, including antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. It also develops ENV 105, an antibody therapeutic that is in a Phase 2 clinical trial for prostate cancer patients resistant to androgen-targeted therapy, as well as in a Phase 1 clinical trial for non-small cell lung cancer. In addition, the company's products under the preclinical stage include KROS 201 that activates T cells using dendritic cells for the treatment of patients with glioblastoma; KROS 101, an orally available glucocorticoid-induced tumor necrosis factor receptor (GITR) ligand small-molecule antagonist designed to deplete regulatory T cells (Tregs) and activate effector T cells to augment the antitumor immune response for the treatment of patients with cancer, as well as a systemic immune modulator to address immunosuppressive activity of solid cancers; KROS 102, a GITR antagonist to increase the inhibitory regulatory Tregs functions for the treatment of autoimmune disease; KROS 301, a tumor-targeting small molecule and checkpoint inhibitor that targets tumor cells in RelA/p65 biomarker-positive solid tumors for the treatment of triple-negative breast cancer; KROS 401, a tumor microenvironment immune modulator and cyclic peptide inhibitor of IL-4 and IL-13, reversing tumor associated macrophage inhibition that blocks the IL4/IL13 cytokine immune receptors for the treatment of triple-negative breast cancer; and ENV 205, an antibody fragment that targets mitochondrial DNA for the treatment of prostate cancer. The company was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. Kairos Pharma, Ltd. was incorporated in 2013 and is based in Los Angeles, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$8.00
Mean price target
2. Current target
$0.44
Latest analyst target
3. DCF / Fair value
$-1.52
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.44
Low
$4.00
High
$12.00
Mean
$8.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-11-19 main D. Boral Capital Buy → Buy $9
2025-11-04 main D. Boral Capital Buy → Buy $9
2025-10-20 main D. Boral Capital Buy → Buy $9
2025-10-07 main D. Boral Capital Buy → Buy $9
2025-09-19 main D. Boral Capital Buy → Buy $9
2025-07-16 main D. Boral Capital Buy → Buy $9
2025-06-04 main D. Boral Capital Buy → Buy $9
2025-04-17 main D. Boral Capital Buy → Buy $9
2025-04-03 init HC Wainwright & Co. — → Buy $12
2025-03-31 main D. Boral Capital Buy → Buy $9
2025-03-27 init Maxim Group — → Buy $4
2025-03-20 main D. Boral Capital Buy → Buy $9
2025-02-26 main D. Boral Capital Buy → Buy $9
2025-02-18 main D. Boral Capital Buy → Buy $9
2025-02-12 main D. Boral Capital Buy → Buy $9
2025-01-22 main D. Boral Capital Buy → Buy $9
2024-11-14 main D. Boral Capital Buy → Buy $9
2024-10-14 init EF Hutton — → Buy $9
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-10-08 SINGHVI RAHUL Director — 19,084 $0.00 $0
2025-10-08 YU JOHN S Chief Executive Officer — 190,840 $0.00 $0
2025-10-08 KEYOUNG HANSOO MICHAEL Director — 29,084 $0.00 $0
2025-10-08 SAMUELSON DOUG Chief Financial Officer — 152,672 $0.00 $0
2025-10-08 BHOWMICK NEIL PH.D. Officer — 171,756 $0.00 $0
2025-10-08 BAE HYUN W. M.D. Director — 29,084 $0.00 $0
2025-10-08 MURALI RAMACHANDRAN PH.D. Officer — 152,672 $0.00 $0
2024-12-31 YU JOHN S Chief Executive Officer — 14,000 $0.00 $0
2024-12-31 BHOWMICK NEIL PH.D. Officer — 14,000 $0.00 $0
2024-12-31 MURALI RAMACHANDRAN PH.D. Officer — 14,000 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
5.57
+137.81%
2.34
+36.70%
1.71
+200.18%
0.57
Research And Development
2.13
+415.70%
0.41
+404.88%
0.08
-5.75%
0.09
Selling General And Administration
3.28
+85.25%
1.77
+20.18%
1.47
+354.32%
0.32
General And Administrative Expense
3.28
+85.25%
1.77
+20.18%
1.47
+354.32%
0.32
Salaries And Wages
0.34
+55.71%
0.22
-76.01%
0.91
0.00
Other Gand A
2.55
+82.34%
1.40
+163.96%
0.53
+74.34%
0.30
Total Expenses
5.57
+137.81%
2.34
+36.70%
1.71
+200.18%
0.57
Operating Income
-5.57
-137.81%
-2.34
-36.70%
-1.71
-200.18%
-0.57
Total Operating Income As Reported
-5.57
-137.81%
-2.34
-36.70%
-1.71
-200.18%
-0.57
EBITDA
-5.29
-134.56%
-2.25
-45.05%
-1.55
-260.56%
-0.43
Normalized EBITDA
-5.29
-85.31%
-2.85
-83.59%
-1.55
-260.56%
-0.43
Reconciled Depreciation
0.16
+0.00%
0.16
+0.00%
0.16
+0.00%
0.16
EBIT
-5.45
-125.64%
-2.41
-40.84%
-1.71
-190.02%
-0.59
Total Unusual Items
0.00
-100.00%
0.60
0.00
—
Total Unusual Items Excluding Goodwill
0.00
-100.00%
0.60
0.00
—
Special Income Charges
0.00
-100.00%
0.60
0.00
—
Other Special Charges
—
-0.60
—
—
Net Income
-5.45
-109.26%
-2.60
-43.65%
-1.81
-72.57%
-1.05
Pretax Income
-5.45
-109.26%
-2.60
-43.65%
-1.81
-72.57%
-1.05
Net Non Operating Interest Income Expense
0.12
+114.55%
-0.86
-776.53%
-0.10
+79.54%
-0.48
Interest Expense Non Operating
0.00
-100.00%
0.19
+92.86%
0.10
-78.65%
0.46
Net Interest Income
0.12
+114.55%
-0.86
-776.53%
-0.10
+79.54%
-0.48
Interest Expense
0.00
-100.00%
0.19
+92.86%
0.10
-78.65%
0.46
Interest Income Non Operating
0.12
0.00
—
—
Interest Income
0.12
0.00
—
—
Other Income Expense
—
0.60
—
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-5.45
-109.26%
-2.60
-43.65%
-1.81
-72.57%
-1.05
Net Income From Continuing Operation Net Minority Interest
-5.45
-109.26%
-2.60
-43.65%
-1.81
-72.57%
-1.05
Net Income From Continuing And Discontinued Operation
-5.45
-109.26%
-2.60
-43.65%
-1.81
-72.57%
-1.05
Net Income Continuous Operations
-5.45
-109.26%
-2.60
-43.65%
-1.81
-72.57%
-1.05
Normalized Income
-5.45
-70.11%
-3.20
-76.71%
-1.81
-72.57%
-1.05
Net Income Common Stockholders
-5.45
-109.26%
-2.60
-43.65%
-1.81
-72.57%
-1.05
Diluted EPS
-0.30
-30.43%
-0.23
-42.36%
-0.16
-61.56%
-0.10
Basic EPS
-0.30
-30.43%
-0.23
-42.36%
-0.16
-61.56%
-0.10
Basic Average Shares
18.43
+62.27%
11.36
+1.25%
11.22
+3.47%
10.84
Diluted Average Shares
18.43
+62.27%
11.36
+1.25%
11.22
+3.47%
10.84
Diluted NI Availto Com Stockholders
-5.45
-109.26%
-2.60
-43.65%
-1.81
-72.57%
-1.05
Amortization
0.16
+0.00%
0.16
+0.00%
0.16
+0.00%
0.16
Amortization Of Intangibles Income Statement
0.16
+0.00%
0.16
+0.00%
0.16
+0.00%
0.16
Depreciation Amortization Depletion Income Statement
0.16
+0.00%
0.16
+0.00%
0.16
+0.00%
0.16
Depreciation And Amortization In Income Statement
0.16
+0.00%
0.16
+0.00%
0.16
+0.00%
0.16
Insurance And Claims
0.39
+154.97%
0.15
+420.69%
0.03
+45.00%
0.02
Total Other Finance Cost
—
0.67
+1096.43%
0.06
+180.00%
0.02
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
6.54
+13.38%
5.77
+497.72%
0.96
-6.85%
1.04
Current Assets
5.39
+29.22%
4.17
+4027.72%
0.10
-76.89%
0.44
Cash Cash Equivalents And Short Term Investments
4.49
+253.07%
1.27
+1267.74%
0.09
-78.72%
0.44
Cash And Cash Equivalents
4.49
+253.07%
1.27
+1267.74%
0.09
-78.72%
0.44
Cash Financial
—
1.27
+1267.74%
0.09
-78.72%
0.44
Prepaid Assets
0.84
-70.44%
2.86
0.00
0.00
Other Current Assets
0.05
+34.21%
0.04
+375.00%
0.01
—
Total Non Current Assets
1.15
-27.89%
1.60
+85.07%
0.86
+44.24%
0.60
Goodwill And Other Intangible Assets
0.06
-72.07%
0.22
-41.88%
0.38
-29.52%
0.54
Other Intangible Assets
0.06
-72.07%
0.22
-41.88%
0.38
-29.52%
0.54
Non Current Deferred Assets
1.09
-20.77%
1.38
+185.68%
0.48
+745.61%
0.06
Total Liabilities Net Minority Interest
0.20
-79.94%
0.99
-67.40%
3.04
+37.38%
2.21
Current Liabilities
0.20
-79.94%
0.99
-58.75%
2.40
+47.27%
1.63
Payables And Accrued Expenses
0.20
-79.94%
0.99
-58.75%
2.40
+47.27%
1.63
Payables
0.20
-79.94%
0.99
-58.75%
2.40
+47.27%
1.63
Accounts Payable
0.20
-79.94%
0.99
-58.68%
2.40
+47.39%
1.63
Current Debt And Capital Lease Obligation
—
—
—
—
Current Debt
—
—
—
—
Other Current Borrowings
—
—
—
—
Total Non Current Liabilities Net Minority Interest
0.00
0.00
-100.00%
0.64
+9.62%
0.58
Long Term Debt And Capital Lease Obligation
—
—
0.64
+9.62%
0.58
Long Term Debt
—
—
0.64
+9.62%
0.58
Stockholders Equity
6.34
+32.77%
4.78
+329.84%
-2.08
-76.25%
-1.18
Common Stock Equity
6.34
+32.77%
4.78
+329.84%
-2.08
-76.25%
-1.18
Capital Stock
0.02
+50.00%
0.01
+27.27%
0.01
+10.00%
0.01
Common Stock
0.02
+50.00%
0.01
+27.27%
0.01
+10.00%
0.01
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
20.82
+51.58%
13.74
+6.97%
12.84
+0.00%
12.84
Ordinary Shares Number
20.82
+51.58%
13.74
+6.97%
12.84
+0.00%
12.84
Additional Paid In Capital
20.58
+51.59%
13.58
+229.30%
4.12
+28.40%
3.21
Retained Earnings
-14.26
-61.79%
-8.81
-41.90%
-6.21
-41.18%
-4.40
Total Equity Gross Minority Interest
6.34
+32.77%
4.78
+329.84%
-2.08
-76.25%
-1.18
Total Capitalization
6.34
+32.77%
4.78
+431.67%
-1.44
-141.21%
-0.60
Working Capital
5.19
+63.30%
3.18
+237.89%
-2.30
-92.64%
-1.20
Invested Capital
6.34
+32.77%
4.78
+431.67%
-1.44
-141.21%
-0.60
Total Debt
—
—
0.64
+9.62%
0.58
Net Debt
—
—
0.55
+275.86%
0.14
Net Tangible Assets
6.28
+37.88%
4.55
+285.12%
-2.46
-42.94%
-1.72
Tangible Book Value
6.28
+37.88%
4.55
+285.12%
-2.46
-42.94%
-1.72
Current Notes Payable
—
—
—
0.00
Dueto Related Parties Current
—
0.00
-100.00%
0.00
+0.00%
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-3.44
+13.00%
-3.96
-4982.72%
0.08
+122.95%
-0.35
Cash Flow From Continuing Operating Activities
-3.44
+13.00%
-3.96
-4982.72%
0.08
+122.95%
-0.35
Net Income From Continuing Operations
-5.45
-109.26%
-2.60
-43.65%
-1.81
-72.57%
-1.05
Depreciation Amortization Depletion
0.16
+0.00%
0.16
+0.00%
0.16
+0.00%
0.16
Amortization Cash Flow
0.16
+0.00%
0.16
+0.00%
0.16
+0.00%
0.16
Depreciation And Amortization
0.16
+0.00%
0.16
+0.00%
0.16
+0.00%
0.16
Amortization Of Intangibles
0.16
+0.00%
0.16
+0.00%
0.16
+0.00%
0.16
Other Non Cash Items
2.65
+498.65%
0.44
-54.28%
0.97
+137.50%
0.41
Stock Based Compensation
—
0.22
0.00
0.00
Operating Gains Losses
—
0.03
—
—
Gain Loss On Investment Securities
—
0.03
—
—
Change In Working Capital
-0.81
+59.38%
-1.98
-359.69%
0.76
+492.25%
0.13
Change In Prepaid Assets
-0.01
+99.46%
-2.39
-29750.00%
-0.01
0.00
Change In Payables And Accrued Expense
-0.79
-296.29%
0.40
-47.67%
0.77
+498.45%
0.13
Change In Other Working Capital
—
-2.36
—
—
Investing Cash Flow
—
—
—
0.00
Cash Flow From Continuing Investing Activities
—
—
—
0.00
Net Other Investing Changes
—
—
—
—
Financing Cash Flow
6.66
+29.72%
5.13
+1308.00%
-0.42
-159.27%
0.72
Cash Flow From Continuing Financing Activities
6.66
+29.72%
5.13
+1308.00%
-0.42
-159.27%
0.72
Net Issuance Payments Of Debt
0.00
0.00
0.00
-100.00%
0.90
Issuance Of Debt
0.00
-100.00%
0.14
0.00
-100.00%
0.93
Repayment Of Debt
—
-0.14
0.00
+100.00%
-0.03
Long Term Debt Issuance
0.00
-100.00%
0.14
0.00
-100.00%
0.93
Long Term Debt Payments
—
-0.14
0.00
+100.00%
-0.03
Net Long Term Debt Issuance
0.00
0.00
0.00
-100.00%
0.90
Short Term Debt Issuance
—
—
—
—
Short Term Debt Payments
—
—
—
—
Net Short Term Debt Issuance
—
—
—
—
Net Common Stock Issuance
0.00
-100.00%
5.52
0.00
0.00
Proceeds From Stock Option Exercised
3.06
0.00
—
—
Net Other Financing Charges
3.60
+1023.59%
-0.39
+8.24%
-0.42
-138.76%
-0.18
Changes In Cash
3.22
+173.03%
1.18
+442.73%
-0.34
-194.51%
0.36
Beginning Cash Position
1.27
+1267.74%
0.09
-78.72%
0.44
+498.63%
0.07
End Cash Position
4.49
+253.07%
1.27
+1267.74%
0.09
-78.72%
0.44
Free Cash Flow
-3.44
+13.00%
-3.96
-4982.72%
0.08
+122.95%
-0.35
Interest Paid Supplemental Data
0.00
-100.00%
0.00
0.00
0.00
Income Tax Paid Supplemental Data
0.00
0.00
0.00
0.00
Common Stock Issuance
0.00
-100.00%
5.52
0.00
0.00
Issuance Of Capital Stock
0.00
-100.00%
5.52
0.00
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category